Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion

EBioMedicine

Volumn 10, Issue , 2016, Pages 185-194

  Salunkhe, Vishal A ^a   Mollet, Inês G ^a   Ofori, Jones K ^a   Malm, Helena A ^a   Esguerra, Jonathan L S ^a   Reinbothe, Thomas M ^c   Stenkula, Karin G ^b   Wendt, Anna ^a   Eliasson, Lena ^a   Vikman, Jenny ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adipose tissue; Beta cell; Ca2 + measurements; Glucose homeostasis; Glucose uptake; Insulin secretion; Islet; Muscle; OGTT; Statin; Transmission electron microscopy

Indexed keywords

CALCIUM; GLUCOSE; MESSENGER RNA; ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; CELL ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HISTOGRAPHY; HORMONE DETERMINATION; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; HOMEOSTASIS; INSULIN RESISTANCE; METABOLISM; PANCREAS ISLET BETA CELL; SECRETION (PROCESS);

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CALCIUM; CALCIUM SIGNALING; DIET, HIGH-FAT; FEMALE; GLUCOSE; HOMEOSTASIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; ROSUVASTATIN CALCIUM;

EID: 85027956948     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.07.007     Document Type: Article

References (35)

1. Bugliani, M., Syed, F., Masini, M., Marselli, L., Suleiman, M., Novelli, M., Filipponi, F., Boggi, U., Masiello, P., De Tata, V., et al. Direct effects of rosuvastatin on pancreatic human beta cells. Acta Diabetol. 50 (2013), 983–985.
2. Cederberg, H., Stancakova, A., Yaluri, N., Modi, S., Kuusisto, J., Laakso, M., Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 58 (2015), 1109–1117.
3. Chen, Z.Y., Liu, S.N., Li, C.N., Sun, S.J., Liu, Q., Lei, L., Gao, L.H., Shen, Z.F., Atorvastatin helps preserve pancreatic beta cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids Health Dis., 13, 2014, 98.
4. Christensen, G.L., Jacobsen, M.L., Wendt, A., Mollet, I.G., Friberg, J., Frederiksen, K.S., Meyer, M., Bruun, C., Eliasson, L., Billestrup, N., Bone morphogenetic protein 4 inhibits insulin secretion from rodent beta cells through regulation of calbindin1 expression and reduced voltage-dependent calcium currents. Diabetologia 58 (2015), 1282–1290.
5. Francisco, A.B., Singh, R., Sha, H., Yan, X., Qi, L., Lei, X., Long, Q., Haploid insufficiency of suppressor enhancer Lin12 1-like (SEL1L) protein predisposes mice to high fat diet-induced hyperglycemia. J. Biol. Chem. 286 (2011), 22275–22282.
6. Fushiki, T., Wells, J.A., Tapscott, E.B., Dohm, G.L., Changes in glucose transporters in muscle in response to exercise. Am. J. Phys. 256 (1989), E580–E587.
7. Gannage-Yared, M.H., Azar, R.R., Amm-Azar, M., Khalife, S., Germanos-Haddad, M., Neemtallah, R., Halaby, G., Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54 (2005), 947–951.
8. Gliemann, J., Rees, W.D., Foley, J.A., The fate of labelled glucose molecules in the rat adipocyte. Dependence on glucose concentration. Biochim. Biophys. Acta 804 (1984), 68–76.
9. Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., Lenfant, C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004), 433–438.
10. Guclu, F., Ozmen, B., Hekimsoy, Z., Kirmaz, C., Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed. Pharmacother. 58 (2004), 614–618.
11. Jula, A., Marniemi, J., Huupponen, R., Virtanen, A., Rastas, M., Ronnemaa, T., Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 287 (2002), 598–605.
12. Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H., Choi, I.S., Shin, E.K., Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol. 45 (2005), 1649–1653.
13. Li, G., Regazzi, R., Roche, E., Wollheim, C.B., Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins. Biochem. J. 289:Pt 2 (1993), 379–385.
14. Matsuda, M., DeFronzo, R.A., Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999), 1462–1470.
15. Mora, S., Glynn, R.J., Hsia, J., MacFadyen, J.G., Genest, J., Ridker, P.M., Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121 (2010), 1069–1077.
16. Ohmura, C., Watada, H., Hirose, T., Tanaka, Y., Kawamori, R., Acute onset and worsening of diabetes concurrent with administration of statins. Endocr. J. 52 (2005), 369–372.
17. Okada, K., Maeda, N., Kikuchi, K., Tatsukawa, M., Sawayama, Y., Hayashi, J., Pravastatin improves insulin resistance in dyslipidemic patients. J. Atheroscler. Thromb. 12 (2005), 322–329.
18. Pacini, G., Omar, B., Ahren, B., Methods and models for metabolic assessment in mice. J. Diabetes Res., 2013, 2013, 986906.
19. Paoletti, R., Fahmy, M., Mahla, G., Mizan, J., Southworth, H., Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk 8 (2001), 383–390.
20. Paolisso, G., Sgambato, S., De Riu, S., Gambardella, A., Verza, M., Varricchio, M., D'Onofrio, F., Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur. J. Clin. Pharmacol. 40 (1991), 27–31.
21. Preiss, D., Sattar, N., Pharmacotherapy: statins and new-onset diabetes—the important questions. Nat. Rev. Cardiol. 9 (2012), 190–192.
22. 2 +]c and role of SERCA2b and SERCA3. Diabetes 60 (2011), 2533–2545.
23. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359 (2008), 2195–2207.
24. Rodbell, M., Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 239 (1964), 375–380.
25. Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C.R., Magni, P., Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur. J. Intern. Med. 25 (2014), 401–406.
26. Salunkhe, V.A., Elvstam, O., Eliasson, L., Wendt, A., Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells. PLoS One, 11(3), 2016 Mar 17, e0151592, 10.1371/journal.pone.0151592 eCollection 2016.
27. Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Seshasai, S.R., McMurray, J.J., Freeman, D.J., Jukema, J.W., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
28. Sonmez, A., Baykal, Y., Kilic, M., Yilmaz, M.I., Saglam, K., Bulucu, F., Kocar, I.H., Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 22 (2003), 151–154.
29. Stenkula, K.G., Lizunov, V.A., Cushman, S.W., Zimmerberg, J., Insulin controls the spatial distribution of GLUT4 on the cell surface through regulation of its postfusion dispersal. Cell Metab. 12 (2010), 250–259.
30. Thiebaud, D., Jacot, E., DeFronzo, R.A., Maeder, E., Jequier, E., Felber, J.P., The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31 (1982), 957–963.
31. Vikman, J., Jimenez-Feltstrom, J., Nyman, P., Thelin, J., Eliasson, L., Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 23 (2009), 58–67.
32. Winzell, M.S., Ahren, B., The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53:Suppl. 3 (2004), S215–S219.
33. 2 + channels in rat islet beta-cells. Br. J. Pharmacol. 126 (1999), 1205–1213.
34. Zhao, W., Zhao, S.P., Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des. Devel. Ther. 9 (2015), 6211–6223.
35. Zhou, J., Li, W., Xie, Q., Hou, Y., Zhan, S., Yang, X., Xu, X., Cai, J., Huang, Z., Effects of simvastatin on glucose metabolism in mouse MIN6 cells. Journal of Diabetes Res., 2014, 2014, 376570.